Prof. Dr. med. Andreas Engert
Hodgkin lymphoma (also called Hodgkin’s disease) is a rare malignant disease of the lymphatic system which predominantly affects younger people. Without therapy, this illness is fatal. However, with survival rates of 80 to 90 per cent, Hodgkin lymphoma is one of the cancer types that responds best to therapy.
Hodgkin lymphoma usually begins with painless swelling of the lymph nodes in the neck. Other symptoms can include fever that cannot be otherwise explained, strong night sweats or a loss of vitality.
Modern diagnostics and forms of therapy
Hodgkin lymphoma is treated with chemotherapy and sometimes with additional radiation therapy. Which therapy is the most suitable varies from one patient to the next and also depends on the stage of the disease.
At the CIO ∙ Cancer Center Cologne you will be examined extensively by experienced specialists and treated on the basis of our findings. Thanks to the internationally recognised therapy success achieved by the German Hodgkin Study Group (GHSG), our experts not only have access to the entire range of modern diagnostics and therapy, they can also offer the newest forms of treatment. The therapy forms are chosen so as to minimise possible side-effects and after-effects.
The CIO ∙ Cancer Center Cologne is setting standards in research into the treatment of Hodgkin lymphoma
The CIO ∙ Cancer Center Cologne has played a key role in improving the treatment of Hodgkin lymphoma. Our patients especially benefit from the fact that the German Hodgkin Study Group is located on the premises of University Hospital Cologne and this provides fast access to new therapy methods.
The German Hodgkin Study Group (GHSG) was initiated by Prof. Dr. Volker Diehl who headed the group until 2004. Since then, the Group has been managed by Prof. Dr. Andreas Engert. For more than 30 years, the GHSG has been examining ways to improve Hodgkin lymphoma diagnostics, treatment and follow-up care. Since 1983, the Study Group has been based University Hospital Cologne. During this time, more than 15,000 patients have participated in numerous trials. The findings of the Study Group have been acknowledged internationally and have defined new standards for therapy. Based on the findings of the trials, the cure rates for Hodgkin lymphoma have been improved significantly during all stages of the disease, and the side-effects of therapy have been greatly reduced. The CIO ∙ Cancer Center Cologne has thus considerably helped to improve the cure rates for Hodgkin lymphoma which now has one of the best cure rates of all forms of cancer.